Up to now, the application of anti-LamR antibodies to interrupt its functionality is a commonly studied in vitro and in vivo approach in potential therapies, e.g., cancers, neuroblastoma, or Alzheimer’s disease (Chetty et al., 2014; Rebelo et al., 2016; Vania et al., 2016; Ferreira et al., 2018). This evidence concerns the gene RPSA and early-onset autosomal dominant Alzheimer disease.